Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: A 9-year single institute experience in the northern region of Thailand

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 1101-1106

  Choeyprasert, Worawut ^a   Natesirinilkul, Rungrote ^a   Charoenkwan, Pimlak ^a   Sittipreechacharn, Somjai ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Carboplatin; Outcome; Pediatric osteosarcoma; Risk factors; Survival; Thailand

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CARBOPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADJUVANT THERAPY; ADOLESCENT; ARTICLE; BONE TUMOR; CHILD; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG TUMOR; MALE; METASTASIS; MORTALITY; OSTEOSARCOMA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; SURVIVAL RATE; THAILAND; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; METHOTREXATE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL; SURVIVAL RATE; THAILAND; TREATMENT OUTCOME;

EID: 84877637233     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.1101     Document Type: Article

References (40)

1. Bacci G, Briccoli A, Ferrari S, et al (2001). Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer, 37, 2030-9.
2. Bacci G, Briccoli A, Longhi A, et al (2005). Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol, 44, 748-55.
3. Bergman PJ, MacEwen EG, Kurzman ID, et al (1996). Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med, 10, 76-81.
4. Bramwell VH, Burgers M, Sneath R, et al (1992). A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 10, 1579-91.
5. Cortes EP, Holland JF, Wang JJ, et al (1972). Doxorubicin in disseminated osteosarcoma. JAMA, 221, 1132-8.
6. Cortes EP, Holland JF, Wang JJ, et al (1974). Amputation and adriamycin in primary osteosarcoma. N Engl J Med, 291, 998-1000.
7. Coventry MB, Dahlin DC (1957). Osteogenic sarcoma; a critical analysis of 430 cases. J Bone Joint Surg Am, 39, 57-8.
8. Crnalic S, Bergstrom P, Lofvenberg R, et al (1996). Antagonistic effect of amphotericin B on carboplatin antitumor activity in human osteosarcoma xenografts. Anticancer Drugs, 7, 489-92.
9. Dahlin DC, Coventry MB (1967). Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am, 49, 101-10.
10. Dahlin DC (1978). Osteosarcoma of bone and a consideration of prognostic variables. Cancer Treat Rep, 62, 189-92.
11. Daw NC, Neel MD, Rao BN, et al (2011). Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 Trial. Cancer, 117, 2770-8.
12. Delepine N, Delepine G, Bacci G, et al (1996). Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer, 78, 2127-35.
13. Eilber F, Giuliano A, Eckardt J, et al (1987). Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol, 5, 21-6.
14. Ferguson WS, Harris MB, Goorin AM, et al (2001). Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol, 23, 340-8.
15. Ferrari S, Bertoni F, Mercuri M, et al (2001). Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol, 12, 1145-50.
16. Fletcher CD (2006). The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology, 48, 3-12.
17. Gaffney R, Unni KK, Sim FH, et al (2006). Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era. Hum Pathol, 37, 1009-14.
18. Hagleitner MM, Hoogerbrugge PM, van der Graaf WT, et al (2011). Age as prognostic factor in patients with osteosarcoma. Bone, 49, 1173-7.
19. Hudson M, Jaffe MR, Jaffe N, et al (1990). Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol, 8, 1988-97.
20. Jaffe N, Paed D, Farber S, et al (1973). Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer, 31, 1367-73.
21. Lee JA, Kim MS, Kim DH, et al (2009). Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr Blood Cancer, 52, 340-5.
22. Lewis IJ, Weeden S, Machin D, et al (2000). Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol, 18, 4028-37.
23. Lewis IJ, Nooij MA, Whelan J, et al (2007). Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst, 99, 112-28.
24. Link MP, Goorin AM, Miser AW, et al (1986). The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med, 314, 1600-6.
25. Lokich J, Anderson N (1998). Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol, 9, 13-21.
26. Mankin HJ, Hornicek FJ, Rosenberg AE, et al (2004). Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res, 429, 286-91.
27. Meyer WH, Pratt CB, Poquette CA, et al (2001). Carboplatin/ ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol, 19, 171-82.
28. Mirabello L, Troisi RJ, Savage SA (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer, 115, 1531-43.
29. Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer, 125, 229-34.
30. Petrilli AS, Kechichian R, Broniscer A, et al (1999). Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma. Med Pediatr Oncol, 33, 71-5.
31. Pratt CB, Howarth C, Ransom JL, et al (1980). High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma. Cancer Treat Rep, 64, 11-20.
32. Robson H, Meyer S, Shalet SM, et al (2002). Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Med Pediatr Oncol, 39, 573-80.
33. Saeter G, Alvegard TA, Elomaa I, et al (1991). Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol, 9, 1766-75.
34. Smith MA, Seibel NL, Altekruse SF, et al (2010). Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol, 28, 2625-34.
35. Stiller CA, Craft AW, Corazziari I (2001). Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer, 37, 760-6.
36. Stiller CA, Bielack SS, Jundt G, et al (2006). Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer, 42, 2124-35.
37. Souhami RL, Craft AW, Van der Eijken JW, et al (1997). Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet, 350, 911-7.
38. Van Winkle P, Angiolillo A, Krailo M, et al (2005). Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/ refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer, 44, 338-47.
39. Wiangnon S, Veerakul G, Nuchprayoon I, et al (2011). Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. Asian Pac J Cancer Prev, 12, 2215-20.
40. Wiromrat P, Jetsrisuparb A, Komvilaisak P, et al (2012). Incidence and survival rates among pediatric osteogenic sarcoma cases in Khon Kaen, Thailand, 1985-2010. Asian Pac J Cancer Prev, 13, 4281-4.